跳至主要内容
临床试验/NCT01973361
NCT01973361已完成不适用

A Randomized Controlled Trial to Investigate if Application of Low Frequency Ultrasound-assisted Debridement May Improve Healing and Infection Outcomes for the Person With Vasculopathy and Recalcitrant Wounds of the Lower Extremity

Ottawa Hospital Research Institute2 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2013年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
78
试验地点
2
主要终点
Change in wound surface area

研究概览

简要总结

The UltraHeal Study is a randomized controlled trial to compare healing response of low frequency contact ultrasonic-assisted debridement in addition to best practice wound care to best practice wound care alone in a Vascular Surgery Clinic patient population with wounds of the lower extremity.

详细描述

The study will also investigate the bacterial tissue burden and protease activity to provide further insight into the infection and inflammation aspects of healing barriers in a challenging population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Persons with lower extremity wound referred to vascular surgery service.
  • Full thickness wound below the knee with surface area of at least 1cm
  • Age >18 years
  • English speaking
  • Ulcer of known etiology including diabetic foot wounds, and arterial or venous leg ulcers
  • Willing and able to adhere to 12 week study protocol that includes attending weekly clinic appointments, and wearing prescribed footwear or compression therapy

排除标准

  • Leg wounds due to inflammatory conditions (e.g. pyoderma gangrenosum, vasculitis), malignancy, or other unknown etiologies.
  • Severe arterial insufficiency: Absence of pedal pulses combined with Ankle Brachial Index ≤ 0.3, Toe Pressure ≤20, or Trans Cutaneous Oxygen Measure ≤20
  • Presence of acute limb threatening infection
  • Vascular surgery planned within next 3 months
  • Exposed vascular graft or blood vessel, bone or tendon in the base of the wound.
  • Currently receiving advanced wound therapy treatments: Hyperbaric therapy, biological dressings [collagen or extracellular matrix dressings].
  • Increased likelihood of an adverse reaction to ultrasonic debridement due to:
  • Excessive wound pain (>5 VAS scale) or patient described intolerable
  • Allergy to topical anesthetic (lidocaine)
  • Individuals who have factors/circumstances that are known to limit their ability to demonstrate healing in 4 weeks.
  • For example:
  • medically unstable or palliative medical status
  • poor nutritional status (low serum albumin < 15),
  • anemia (Hb < 75 mg/dl),
  • taking immunosuppressant medication (prednisone, chemotherapy; transplant anti-rejection medication),
  • Individuals with medical conditions that contraindicate the use of ultrasound energy
  • Cardiac pacemaker or defibrillator
  • Excessive bleeding tendency (> 5 mins post debridement) or identified coagulopathic disorders
  • Exposed bone in the wound base
  • Untreated osteomyelitis

结局指标

主要结局

Change in wound surface area

时间窗: Weekly for 4 weeks then at 12 weeks.

The wound surface area will be measured weekly once treatment is initiated, with a final measurement 12 weeks after initiation of therapy.

次要结局

  • Protease activity(Pre-treatment, post treatment at weeks 5 and weeks then at 12 weeks.)
  • Bacterial burden(Pre-treatment, week 5 and week 12)
  • Number of wounds healed(Throughout duration of the study)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Efficacy Study of Ultrasound-Assisted Debridement to... | 临床试验